MONROVIA, CA — Cell Care Therapeutics Inc., a biotechnology company whose mission is to advance stem-cell derived therapies in ophthalmology, announced the closing of a $4.3 million seed round investment.
The money comes from a syndicate of individual investors. This round of funding will be used to develop Cell Care’s manufacturing platform and to advance its lead preclinical-stage drug candidate for major eye diseases, including diabetic retinopathy and neovascular age-related macular degeneration.
Cell Care is pioneering the development of regenerative immunotherapy, which the company describes as “a new therapeutic approach that has the potential to modulate the immune response in a way that leads to reduced inflammation, permits recovery, and promotes tissue remodeling.”
“The closing of this first round of financing is an endorsement of our novel approach of using stem cell secretions to modulate the immune system as an alternative to the more commercially challenging approach of using living cells to repair damaged tissue,” said Nicolas Sohl, president and CEO of Cell Care. “The ophthalmic community is embracing the theory that the treatment of complex degenerative diseases within the eye may require a broader set of signaling molecules that cannot be recapitulated by any single small molecule, RNA, or recombinant protein.”